INDIANAPOLIS--(BUSINESS WIRE)-- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, announced it will be exhibiting at the European Society of Cardiology’s (ESC) International Conference of Non-Invasive Cardiovascular Imaging (ICNC), to be be held in Amsterdam, Netherlands, May 15th to 18th, 2011.
This year’s conference marks a milestone with ICNC’s 20th anniversary, and also signifies Positron’s entrance into the European market. ICNC will provide a unique opportunity for Positron to highlight its Attrius® and PosiRx™ systems and network with the some of the most influential non-invasive cardiologists and cardiovascular imaging specialists from across the world. And with the European market expected to reach $5.6 billion by 2017 (according to TriMark Publications), Positron’s objectives are to bridge its products outside North America with key partnerships and distributors. Positron and/or its affiliates are in the process of attaining the necessary regulatory compliance for its products and expect approval later in 2011 thus, expanding its reach to the extensive European, Canadian and additional International markets.
With a constituency of approximately 68,000 cardiology professionals spanning Europe and the Mediterranean, ESC is the prominent organization well-know for its extensive array of scientific and educational activities. The ESC is very active in the production and continuous updating of clinical practice guidelines, the organization of educational courses and initiatives, pan-European surveys on specific disease areas.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron Corporation, a pioneer in molecular imaging for more than 25 years provides unique solutions for the nuclear medicine community through the production and distribution of proprietary molecular imaging systems and radiopharmaceutical products. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
Patrick Rooney, (317) 576-0183
KEYWORDS: United Kingdom United States Europe North America Netherlands Indiana Germany
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Hospitals Medical Devices Oncology Radiology Other Health